CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition

Uzair Iqbal, Khadija Khalid, Mohamed Shaltout, Yunus Yukselten, Richard E. Sutton · 2026

Read CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition by Uzair Iqbal, Khadija Khalid, Mohamed Shaltout, Yunus Yukselten, Richard E. Sutton (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13611976.txt.

Description

Uzair Iqbal and co-authors review a cell entry point for HIV as a treatment target in a 2026 article. The protein, called CCR5, is the main helper the most common form of the virus uses to enter cells. People born with a natural fault in this protein resist infection, which first pointed to it as a target.

The review covers two attack routes: gene editing that breaks the protein's gene, and a drug that blocks the protein. It weighs lab and early clinical evidence for both, including editing plans meant to stop the virus switching to another entry route. The drug also shows side benefits, such as calming immune activity. The authors see both routes as parts of future combined plans for lasting control of HIV.

Catalog record

CREATORUzair Iqbal, Khadija Khalid, Mohamed Shaltout, Yunus Yukselten, Richard E. Sutton
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13611976

Browse the full library · About the Tower of Babel